For instance, it has been presented by the IMpassion130 study that the therapeutic strategy of atezolizumab (a PD-1/PD-L1 inhibitor) plus albumin paclitaxel as the first-line therapy has improved the overall survival (OS) by 7.5 months and reduced the risk of death by 33%, compared with the placebo plus albumin paclitaxel group, for advanced TNBC patients with PD-L1 positive, marking the beginning of the immunotherapy for breast cancer [39]. This evidence concerns the gene CD274 and breast carcinoma.